Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2024年7月15日 - 9:19PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
July 15, 2024
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 15 July 2024 – On 6 May 2024, Novo
Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and
Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This
programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning
6 February 2024.
Under the programme initiated 6 May 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 2.2 billion in the period from
7 May 2024 to 5 August 2024.
Since the announcement 08 July 2024, the following transactions have been made:
|
Number of
B shares |
Average
purchase price |
Transaction value,
DKK |
Accumulated,
last announcement |
1,512,345 |
|
1,442,717,161 |
8 July
2024 |
36,500 |
981.24 |
35,815,365 |
9 July
2024 |
37,010 |
970.38 |
35,913,631 |
10
July 2024 |
36,965 |
964.30 |
35,645,476 |
11
July 2024 |
38,000 |
973.20 |
36,981,654 |
12
July 2024 |
37,000 |
972.79 |
35,993,373 |
Accumulated
under the programme |
1,697,820 |
|
1,623,066,660 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
Page 2 of 2
With
the transactions stated above, Novo Nordisk owns a total of 11,797,860 B shares of DKK 0.10 as treasury shares, corresponding to 0.3%
of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Novo
Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 12
July 2024, Novo Nordisk has since 6 February 2024 repurchased a total of 10,432,070 B shares at an average share price of DKK 877.18
per B share equal to a transaction value of DKK 9,150,801,432.
Novo
Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat
serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our
medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York
Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
Media: |
|
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com |
Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com |
|
|
Investors: |
|
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com |
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com |
|
|
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com |
Sina Meyer
+45 3079 6656
azey@novonordisk.com |
|
|
Frederik Taylor Pitter
+45 3075 8259
fptr@novonordisk.com |
Ida Melvold Gjøsund
+45 3077 5649
idmg@novonordisk.com |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet:
www.novonordisk.com CVR no:
24 25 67 90 |
| | | Company
announcement No 53 / 2024 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: July 15, 2024 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (NYSE:NVO)
過去 株価チャート
から 7 2024 まで 8 2024
Novo Nordisk (NYSE:NVO)
過去 株価チャート
から 8 2023 まで 8 2024